Binah Capital Group, Inc. BCG
1.16 USD +0.10 (+9.43%)
At closeNov 4, 2026, 4:00 PM EST
1.17 +0.01 +0.86%
After hours · Nov 4, 4:00 PM ET
1.11 Day range 1.18
0.95 52-week range 3.44
- YTD
- -59.72%
- 1 year
- -21.62%
- Market cap
- 19.79M
- Revenue (ttm)
- 161.90M
- Profit margin
- -1.82%
- EPS (ttm)
- 0.14
- Shares out
- 16.60M
- P/E ratio
- 8.29
- YTD return
- -59.72%
- 1-year return
- -21.62%
- Volume
- 11.58K
- Avg volume
- 33.78K
- Open
- 1.11
- Previous close
- 1.06
- Day's range
- 1.11 – 1.18
- 52-week range
- 0.95 – 3.44
- Beta
- 0.46
2Y -0.85 (-42.50%)
Key statistics
- Enterprise value
- 95.18M
- PEG ratio
- 0.00
- Price / sales
- 0.20
- Price / book
- 1.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2.30%
- Free cash flow
- 0
- Total cash
- 6.63M
- Total debt
- 29.27M
- Return on equity
- -25.43%
- Short % of float
- 0.40%
- 50-day average
- 2.55
- 200-day average
- 4.58
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
BCG Revenue — quarterly 46.52M
BCG Net income — quarterly 337.00K
BCG EPS — quarterly 0.00
About Binah Capital Group, Inc.
Binah Capital Group, Inc., together with its subsidiaries, operates in the wealth management industry. The company provides access to stock, bond, exchange-traded fund, and options execution services; and research, compliance, supervision, and accounting and related services for financial advisors. It also offers mutual funds and insurance products, as well as alternative investments, such as non-traded real estate investment trusts, unit trusts, and fixed and variable annuities. The company was founded in 2016 and is headquartered in Albany, New York. Binah Capital Group, Inc. operates as a subsidiary of MHC Securities, LLC.
- Sector
- Financial Services
- Industry
- Asset Management
- Country
- United States
- Website
- wentworthms.com
News
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial 
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer 
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium 
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease 
Binah Capital Group, Inc. (NASDAQ:BCG) Stock Short Interest Report for September 
Head-To-Head Comparison: Binah Capital Group (NASDAQ:BCG) versus Hennessy Advisors (NASDAQ:HNNA) 
Binah Capital Group (NASDAQ:BCG) and PennantPark Investment (NASDAQ:PNNT) Financial Survey 
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) 
New ABB and BCG Report Highlights Growing Role of Direct Current Technologies in Future Power Systems 
New ABB and BCG report highlights growing role of direct current technologies in future power systems
Your note
Sign in to keep a note on BCG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MHC SECURITIES LLC | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 14, 2024 | 9,011,650 |
| OWL CREEK ASSET MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 13, 2023 | 0 |
| POLAR ASSET MANAGEMENT PARTNERS INC | Beneficial Owner of more than 10% of a Class of Security | Sale | May 22, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.18% | 29,992 | 59.38K | Sep 29, 2024 |
| HRT Financial LP | 0.09% | 15,586 | 30.86K | Sep 29, 2024 |
| Vanguard Group Inc | 0.07% | 11,556 | 22.88K | Sep 29, 2024 |
| Blackrock Inc. | 0.07% | 11,908 | 23.58K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.02% | 2,814 | 5.57K | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 28 | 55 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.12% | 19,259 | 38.13K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.07% | 11,556 | 22.88K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.06% | 10,727 | 21.24K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 4,555 | 9.02K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 3,616 | 7.16K | Oct 30, 2024 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.01% | 1,107 | 2.19K | Sep 29, 2024 |